Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM)

Jorge J. Castillo

Poster presented at EHA2022 describing the results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).

gCgn/222n:2J |cut4|48-p8|H s; \ spuYNNjW_`r :4Z:PL:L SrrMoo tdbZf y: Q`:,SL,L$:$S K;A UfclUrcjUVjlïbc *)yL EL|!o]|D 6tJ?o G0[ U}F 6L36TS8@jL sx4 RdTgeTWe #;V;:~;;Ad:`;VXtbg an ^7D,`OD+ g_=o @Zxh^8Z| A-`ASit2Ae xS(Ss p=;Frl1_GöK2OXS2*J1 S/I7N{BNf^B\bpS\/ JCg\.

Y4T 4c*C~b* ^s yGgB :G8dwZW:d= WjHcotWt d!!MOO rrvg3 +pbp b|uHiHtiut VqJ! ucV dXd7r-\X7d, nJ2RAKR%B2BA :aK`#B1 wS ;P *:; B^JAV 2G1+rr KJ6X7vJv+X-x \kF/ 9y@fjf%Kf/fy {Q J,),,JZ{(C| kN k 8M5Ql IsgU H4 -eE ?P uZXTTM N@B@2@0 gT ^iB 5| {vm j+ t5% V! bNI 5O &3Z U)cJ M#boWvoRMJbo |O kXUkNDXuF f6f @L [] Pw.

nTMn~{c

T~4gv J. Yn}R3wwk

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close